ARTICLE SUMMARY:
The Italian corporate venture firm doubled down on its commitment to CoMind this fall, indicating its global interest in connected health and in particular novel approaches to challenging problems in neurological conditions.
Angelini Ventures, the four-year-old fast-growing Rome-based corporate venture arm of the Italian conglomerate Angelini Industries, has designated neurotech and brain health among its priority investment areas.
Under the leadership of Elia Stupka, PhD, managing director, and Paolo Di Giorgio, CEO and managing director, the fund has invested roughly $145 million of its $350 million evergreen fund (€300 million) in 22 start-ups. It has not sought external limited partners, although it is open to the prospect. And it seems to be stepping up its global footprint as the US political climate becomes more challenging for the life sciences.
Stupka headed the firm’s digital health practice in its early days and now leads its charge into Asia. Tanja Dowe, a partner who joined Angelini in 2023 from Switzerland-based Debiopharm Innovation Fund, heads medtech and digital health investments.
